Navigation Links
A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Date:10/25/2007

percent). In post-visit interviews, parents most often reported concern about aggression and defiance; however, these behaviors that parents reported as "most concerning" post-visit were unaddressed in one-third of the visits.

"These results indicate psychiatrists can adopt several techniques to improve in-office communication about complicated ADHD, including structuring visits, so that all voices are heard, discussing comorbidities using language that is more comprehensible to parents, and eliciting parents' expectations at the initiation of treatment," said Dr. Findling. "By focusing on how time is spent and what types of questions are asked of parents and patients, this can lead to successful expectation-setting with both parents and patients. As a result, psychiatrists can have better in-office discussions about ADHD as well as improved treatment of patients suffering from complicated ADHD."

About ADHD

Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). ADHD is one of the most common psychiatric disorders in children and adolescents. The disorder is also estimated to affect 8.1 percent of adults, or approximately 9.2 million adults across the U.S. based on a retrospective survey of adults aged 18 to 44, projected to the full U.S. adult population. ADHD is a neurobiological disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
7. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
11. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...alif., Nov. 20 Bionovo, ... present results from the Phase 1B,clinical trial...tic breast,cancer, BZL101, at the Society for Int...e in Atlanta, Georgia. The Company,s oral present...will be presented as a part of the Best of the,SI...
(Date:11/20/2008)...20 PAREXEL International...iopharmaceutical services provider, today announce...ovide regulatory consulting and clinical research ..., PAREXEL now has locations throughout five import...ich also include Argentina, Brazil, Chile, and Mex...
(Date:11/19/2008)...tudy did not achieve statistical significance , ...l/ -- Pharmos Corporation (Nasdaq: PARS ) today ... of its topical NanoEmulsion (NE) drug delivery te...ine. , , The multi-center, randomized, doub... safety and efficacy of the Company,s 3% Diclofena...
(Date:11/19/2008)...Million Payment from Roche- , , MONTVALE, N...maceuticals Corp. (Nasdaq: MEMY ) today announce... Phase 2 trial of R3487/MEM 3454, its lead alpha-7...nt associated with schizophrenia (CIAS). The Comp...al, triggering a $5.0 million payment from its par...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Almost Family Reports Third Quarter 2008 Results 28817 1Almost Family Reports Third Quarter 2008 Results 28817 2Almost Family Reports Third Quarter 2008 Results 28817 3Almost Family Reports Third Quarter 2008 Results 28817 4Almost Family Reports Third Quarter 2008 Results 28817 5Almost Family Reports Third Quarter 2008 Results 28817 6Almost Family Reports Third Quarter 2008 Results 28817 7Almost Family Reports Third Quarter 2008 Results 28817 8Almost Family Reports Third Quarter 2008 Results 28817 9Almost Family Reports Third Quarter 2008 Results 28817 10Almost Family Reports Third Quarter 2008 Results 28817 11Almost Family Reports Third Quarter 2008 Results 28817 12Almost Family Reports Third Quarter 2008 Results 28817 13Almost Family Reports Third Quarter 2008 Results 28817 14Almost Family Reports Third Quarter 2008 Results 28817 15Almost Family Reports Third Quarter 2008 Results 28817 16InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 1InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 2InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 3InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 4InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 5InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 6InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 7InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 8InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 9InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 10InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 11Neurobiological Technologies to Present at the Rodman 26 Renshaw 10th Annual Healthcare Conference in New York on November 10 8897 1Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 1Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 3Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 4Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 5Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 6
...E)--Apr 19, 2007 - Gilead Sciences, Inc.,(Nasdaq:G... III,AIR-CF2 study evaluating aztreonam lysine for...c fibrosis (CF) who have,pulmonary Pseudomonas aer...eatment course of aztreonam lysine significantly i...s (IV) antibiotics versus,placebo. All patients re...
... WIRE)--Apr 23, 2007 - CytRx Corporation,(NASDAQ:C...Ai),delivery technology exclusively licensed to it...orporation (RXi), has been,published in the April ... Chemical Biology. The technology was developed by...and University of,Massachusetts Medical School (UM...
Other Medicine Technology:Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
(Date:11/21/2008)...Call/ -- The Providence Service,Corporation (Nasd... the Company,s,Chief Operating Officer, has been ...r. Norris, appointment fills the vacancy left by t...nd returns the board to six members. Mr.,Norris ... Mr. Norris, age 41, has been with Providence ...
(Date:11/21/2008)...ainst Lennox-Gastaut syndrome , , FRIDAY...nzel (rufinamide) has been approved as a supplemen...d Lennox-Gastaut syndrome, the U.S. Food and Drug ... was based on results of a four-month clinical tri...o patients who took a placebo, those who took the ...
(Date:11/21/2008)...SNewswire/ -- New research at West Virginia Unive...tobacco product aimed at young adults is catching ...s, Camel Snus - touted as a socially acceptable wa...h levels of nicotine. , , "Camel Snus conta... said Bruce Adkins of the state Division of Tobacc...
(Date:11/21/2008)...wswire/ -- U.S. News & World Report and the Na...ed BlueChoice(R) HealthPlan of South Carolina in t...ublished in U.S. News & World Report,s issue t...ranks the nation,s best health plans based on clin...tation scores. NCQA and U.S. News & World Repo...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...n Parry, a 59 year old British grandmother is all ...India after undergoing a surgery// in the Indian c...ial Hospital has cured her of a painful back. Parr...to get the treatment on the UK’s National Health S...
...rwegian study has revealed that anti-depressants l...y inflict damage upon the human skeleton.// The No...NU) researcher Bjorn I. Gustafsson has revealed th...he activity of bone building cells, while raising ...
...archers at the University of North Carolina at Cha...aggressive prostate tumors. The molecule//, labele...ily and triggers aggressiveness in prostate tumors...recting cells to dump a tumor-suppressor protein. ...
...archers have found that exposure to pollutants inc...study was conducted on fisherman families eating//...nd pollutants known as Persistent Organochlorine P... biphenyls (PCBs) and DDT. Type 2 diabetes genera...
Other Medicine News:Health News:Indian Healthcare Facilities Come In For Praise 2
The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia
Inquire
...'000 tests per year through automatic scheduling a... processing up to 4 assays on 4 plates simultaneou...to presentation of the results, are controlled by ... tube rack) and 256 (POS-ID Linear Rack) samples c...
IMMULITE 2000 assays are designed for use with the IMMULITE 2000, a high-throughput, continuous random access immunoassay analyzer. IMMULITE 2000 offers testing efficiency through centralization, and
Medicine Products: